Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

586
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
586
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

451
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
451
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

478
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
478
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

601
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
601
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

487
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
487
Tumor Progression02:07

Tumor Progression

7.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.

Journal of the American Heart Association·2026
Same author

Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Long-term clinical benefit after radiofrequency renal denervation: pooled 36-month results from the SPYRAL Clinical Program.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover Trial.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Blood Pressure Assessment Across the Lifespan: Improving Clinical Research and Clinical Practice: A National Heart, Lung, and Blood Institute Workshop Report.

Journal of the American College of Cardiology·2026
Same author

Five-Year Risk Prediction Models for Peripheral Artery Disease in Patients With Chronic Kidney Disease.

Kidney medicine·2026
Same journal

The Physician Leader: Teaching Leadership in Medicine.

Advances in chronic kidney disease·2022
Same journal

Postgraduate Education and Training for the Nephrology Physician Assistants and Nurse Practitioners.

Advances in chronic kidney disease·2022
Same journal

Evaluation Evolution: Designing Optimal Evaluations to Enhance Learning in Nephrology Fellowship.

Advances in chronic kidney disease·2022
Same journal

Kidney Pathology Education for Nephrology Fellows: Past, Present, and Future.

Advances in chronic kidney disease·2022
Same journal

Clinician Educator Pathway for Nephrology Fellows: The University of North Carolina Experience.

Advances in chronic kidney disease·2022
Same journal

Current Trends and Challenges in Nephrology Fellowship Training: Expansion of Education in Home Dialysis, Palliative Care, and Point-of-Care Ultrasound.

Advances in chronic kidney disease·2022
See all related articles

Related Experiment Video

Updated: Jan 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.1K

Treating Hypertension Using Renal Artery Denervation: Problems and Progress.

Raymond R Townsend1

  • 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

Advances in Chronic Kidney Disease
|April 27, 2019
PubMed
Summary
This summary is machine-generated.

Renal denervation, a therapy for hypertension, showed no significant benefit in a major trial. This review examines factors that may have influenced results and suggests improvements for future renal denervation studies.

Keywords:
Ambulatory blood pressure monitoring (ABPM)HypertensionRadiofrequency ablationRenal artery denervationUltrasound ablation

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

702
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.2K

Related Experiment Videos

Last Updated: Jan 25, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.1K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

702
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

8.2K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Hypertension Management

Background:

  • Renal denervation was investigated as a novel therapy for resistant hypertension.
  • Early studies suggested potential efficacy, generating significant clinical interest.
  • The Symplicity HTN-3 trial aimed to validate these findings in a large, sham-controlled setting.

Purpose of the Study:

  • To review the outcomes of the Symplicity HTN-3 trial for renal denervation.
  • To identify and discuss confounding factors that may have impacted trial results.
  • To explore advancements in trial design for future renal denervation research.

Main Methods:

  • Analysis of the Symplicity HTN-3 trial, a randomized, sham-controlled study.
  • Review of potential procedural and patient-related confounders.
  • Examination of evolving methodologies in renal denervation clinical trials.

Main Results:

  • The Symplicity HTN-3 trial did not demonstrate the superiority of radiofrequency renal denervation over a sham procedure.
  • Results indicated a need to re-evaluate the procedure and trial protocols.
  • The trial's outcome prompted critical assessment of the renal denervation field.

Conclusions:

  • The Symplicity HTN-3 trial yielded unexpected negative results for renal denervation.
  • Understanding confounding factors is crucial for refining future clinical trial designs.
  • Further research is needed to optimize patient selection and procedural techniques for renal denervation.